𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer

✍ Scribed by Won Sang Park; Ro Ra Oh; Young Sil Kim; Jik Young Park; Sug Hyung Lee; Min Sun Shin; Su Young Kim; Pum Joon Kim; Hun Kyung Lee; Nam Jin Yoo; Jung Young Lee


Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
260 KB
Volume
193
Category
Article
ISSN
0022-3417

No coin nor oath required. For personal study only.

✦ Synopsis


It is now believed that genes regulating apoptosis are also important variables in cancer development. Fas, a transmembrane protein of the tumour necrosis factor receptor family, is a key molecule for cell death signalling. The mutation of the primary structure of the Fas gene might also be one of the possible mechanisms that disrupt Fas-mediated apoptosis in tumour cells. The purpose of this study was to determine whether somatic mutation of the Fas gene could be involved in the tumourigenesis of gastric cancer. Polymerase chain reaction (PCR)-based loss of heterozygosity (LOH) analysis with two intragenic polymorphic markers, and mutation analysis for the entire coding regions of the Fas gene were performed in 43 cases of gastric cancer, using PCR-single-strand conformational polymorphism sequencing. Five (11.6%) missense mutations were detected, only in the death domain of the Fas gene. Although these mutations were observed only in intestinal-type gastric cancers, there was no statistically significant difference in the frequency of Fas mutation between intestinal- and diffuse-type gastric cancer (p=0.068). Nine LOH out of 22 informative cases were also detected with one or both markers (41%). Three of them demonstrated a somatic mutation in the remaining allele, indicating the inactivation of both alleles. These results suggest that genetic alterations of the Fas gene may not only be limited to gastric cancer cell protection through Fas resistance, but may also play an important role in tumour promotion and/or progression in a subset of gastric cancer.


πŸ“œ SIMILAR VOLUMES


Resistance to CD95-mediated apoptosis in
✍ Markus MΓΌschen; Daniel Re; Beate Betz; Cordula Moers; JΓΌrgen Wolf; Dieter Nieder πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 45 KB πŸ‘ 1 views

Resistance to CD95 (Apo-1/Fas)-mediated apoptosis is a typical feature of breast cancer cells. Recent studies identified deleterious mutations of the CD95 gene not only in a variety of B cell lymphomas but also in a number of solid tumor entities. Therefore, we amplified and sequenced selected regio

Somatic mutation of the hBUB1 mitotic ch
✍ Akihiko Gemma; Masahiro Seike; Yoko Seike; Kazutsugu Uematsu; Suguru Hibino; Fut πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 140 KB

Mutations in mitotic checkpoint genes have been detected in several human cancers, and these cancers exhibit chromosomal instability. Aneuploid stem cells seem to result from chromosomal instability and have been reported in many lung cancers. To determine whether alteration of mitotic checkpoint re

The spectrum of apoptotic defects and cl
✍ Akshay K. Vaishnaw; Elias Toubi; Satomi Ohsako; Jorn Drappa; Saundra Buys; Jaime πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 300 KB

## Objective: To determine the clinical spectrum of disease in humans with mutations in the cd95 (fas/ apo-1) receptor and to obtain mechanistic insight into the different clinical phenotypes observed. ## Methods: Clinical information for each of the index cases, first-degree relatives, and any f